Study of Intravenous ZMA001 in Healthy Subjects
Sponsored by National Heart, Lung, and Blood Institute (NHLBI)
Compensation
Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.
Duration
3 months
Location
Maryland
About this study
Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people. Objective: To test a dru…
Who can participate
- • Adults aged 18–60
- • All genders welcome
- • Diagnosed with or experiencing pulmonary arterial hypertension pah
- • Able to attend in-person clinic visits
What's included
- • Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
Ready to Find a Research Study?
Explore clinical trials and paid research opportunities. Compensation varies by study and is never guaranteed.